Comparative Pharmacology
Head-to-head clinical analysis: BUSPIRONE HYDROCHLORIDE versus MEPRIAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSPIRONE HYDROCHLORIDE versus MEPRIAM.
BUSPIRONE HYDROCHLORIDE vs MEPRIAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at serotonin 5-HT1A receptors, primarily in the raphe nuclei and hippocampus; also exhibits antagonist properties at presynaptic 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors, resulting in decreased serotonergic activity. Additionally, it has moderate affinity for dopamine D2 receptors (antagonist) and alpha2-adrenergic receptors.
Mepriam is a thiazide-like diuretic that inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride, leading to increased diuresis and vasodilation.
Initial dose: 7.5 mg orally twice daily; may increase by 2.5-5 mg every 2-3 days to a target dose of 15-30 mg/day in divided doses (2-3 times daily). Maximum dose: 60 mg/day divided twice daily.
Adults: 500 mg IV every 24 hours.
None Documented
None Documented
2-3 hours terminal half-life; clinical context: requires multiple daily dosing (3 times daily) due to short half-life; no active metabolites prolonging effect.
The terminal elimination half-life of MEPRIAM is 12–15 hours (mean 13.5 h) in healthy adults, allowing once-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life may extend to 30–40 hours, requiring dose adjustment.
Renal: 29-63% (as metabolites; <1% unchanged); Fecal: 18-38%; Hepatic metabolism primarily via CYP3A4; total clearance 1.5-3.5 L/h/kg.
MEPRIAM is predominantly eliminated via renal excretion (approximately 85% as unchanged drug and metabolites) and about 15% via fecal/biliary routes. Renal clearance accounts for ~70% of total clearance.
Category A/B
Category C
Anxiolytic
Anxiolytic